TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02748551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic procedures
Description: Laparoscopic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Surgery
Description: Open surgery
Study: NCT04030429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: bid orally
Study: NCT01594970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Description: 1 drop in the affected eye(s), administered in the evening for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Description: 1 drop in the affected eye(s), administered in the evening for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Description: 1 drop in the affected eye(s), administered in the evening for 12 weeks.
Study: NCT01367470

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 probiotic preparation
Description: VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo VSL#3
Description: Placebo VSL#3 is a base of corn starch containing no active ingredient.
Study: NCT05101382

Intervention type: OTHER
Intervention: Observation
Description: Retrospective Observation of standard clinical practice
Study: NCT01745575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2mg tablets
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2mg tablets
Description: Reference product
Study: NCT04121455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab every 2 weeks i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab every 2 weeks i.v. infusion
Study: NCT01745575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg tablets
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg tablets
Description: Test product
Study: NCT04121455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab every 2 weeks i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab every 2 weeks i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab every 3 weeks i.v. for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: oral treatment according to current SPC
Study: NCT03602196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal ultrasound assessment
Description: women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral muscles assessment
Description: The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pelvic floor assessment
Description: Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination
Study: NCT01977768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V7
Description: One pill of V7 once daily for 30 days together with standard of care TB drugs

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04293484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal bilateral motor cortex and cathodal spinal tDCS
Description: 10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal bilateral motor cortex and cathodal spinal tDCS
Description: 10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study: NCT02902770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5 mg/kg IV lidocaine drip (given over 10 minutes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: IV ketorolac 30mg push

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: IV ketorolac 30mg push

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Drip
Description: Normal Saline Drip Placebo given over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Push
Description: Normal Saline Push Placebo
Study: NCT04513067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YQ23
Description: YQ23 as a single agent will be given in Stage 1.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given in combination with YQ23 in Stage 2
Study: NCT03399253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: D2 gastrectomy + metastasectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Study: NCT03949400

Intervention type: OTHER
Intervention: Exercise therapy and education.
Description: Exercise therapy and education, physiotherapy rehab at Aalborg Municipality
Study: NCT04532567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: GLPG1205 film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: GLPG1205 film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo film-coated tablets
Study: NCT03771105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphate
Description: The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphate
Description: The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphate
Description: The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphate
Description: The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
Study: NCT03168542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Fitting Guides
Description: Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Fitting Guides
Description: Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
Study: NCT01686737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: * 12 weeks of Iyengar yoga~* 2 weekly sessions of 60 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: * 12 weeks of walking~* 2 weekly sessions of 60 minutes
Study: NCT00543023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide 20 micrograms/day subcutaneous
Study: NCT04293484

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham bilateral motor cortex and sham spinal tDCS
Description: 10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
Study: NCT00543023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmon calcitonin 100 IU/day subcutaneous
Study: NCT01782690

Intervention type: DRUG
Intervention: erlotinib
Description: Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)

Intervention type: DRUG
Intervention: gemcitabine
Description: Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
Study: NCT02086305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitional Care Model
Description: Symptom assessment and management, care goal setting, post-discharge support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care is the routine practice in the hospital

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care is the routine practice in the hospital
Study: NCT01469520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epivir®, Retrovir® and Viramune®
Description: 12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine, Zidovudine and nevirapine
Description: 20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine, Zidovudine and nevirapine
Description: 20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine, zidovudine, nevirapine
Description: Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine, zidovudine, nevirapine
Description: Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
Study: NCT03011762

Intervention type: DEVICE
Group type: OTHER
Intervention: Computer controlled mandibular positioner
Description: Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
Study: NCT01241604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP S/T
Description: Mechanical Non-invasive Ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP Auto SV3
Description: Auto Servo Ventilation Device
Study: NCT04436770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-immersive virtual reality therapy
Description: Non-immersive Virtual Reality (VR) therapy exercises, based on assessment, and occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for upper extremity don't exceed 60 minutes.~For the lower extremity, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for the lower extremity don't exceed 60 minutes.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises using Mirror therapy and alone were used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: Standard physiotherapy program, based on assessment, plus occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~For the lower extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises were used.
Study: NCT03860805

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic tubal ligation
Description: Laparoscopic tubal ligation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic bilateral salpingectomy
Description: Laparoscopic bilateral salpingectomy
Study: NCT04003948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibogaine Hydrochloride
Description: Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibogaine Hydrochloride
Description: Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
Study: NCT04307134

Intervention type: DRUG
Intervention: Inotuzumab ozogamicin
Description: R/R ALL who treated with Inotuzumab ozogamicin
Study: NCT02839031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT (Cognitive-Behavioral Therapy)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control (telephonic support without CBT content)
Study: NCT03488628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Noninvasive ventilation delivered through a face mask, in alternace with satandard nasal oxygen therapy over the first 24 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen therapy
Description: High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher \& Paykel Healthcare,New Zealand) through nasal canula.
Study: NCT00321906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Description: azathioprine 2mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: sirolimus 2-4mg daily
Study: NCT01784926

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraocular lens repositioning by scleral suturing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraocular lens exchange with retropupillary iris-claw lens
Study: NCT01340729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
Study: NCT00845273

Intervention type: DRUG
Intervention: Pegaptanib sodium
Description: Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis ).
Study: NCT01960465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
Study: NCT02388087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROX COUPLER
Description: ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Right heart catheterisation and routine care
Description: Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
Study: NCT02927054

Intervention type: OTHER
Group type: OTHER
Intervention: Sepsis Education
Description: Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis

Intervention type: OTHER
Group type: OTHER
Intervention: Sepsis Education
Description: Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis

Intervention type: OTHER
Group type: OTHER
Intervention: Sepsis Education
Description: Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis

Intervention type: OTHER
Group type: OTHER
Intervention: Sepsis Education
Description: Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis

Intervention type: OTHER
Group type: OTHER
Intervention: Sepsis Education
Description: Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
Study: NCT00558805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FISP + Usual Care

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Study: NCT03167203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
Description: Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
Study: NCT01720524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv sildenafil
Description: loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.